The RNAi Revolution is

DISRUPTING DISEASE

The RNAi Revolution is

DISRUPTING DISEASE

RNAi: A REVOLUTION IN BIOLOGY BUILT ON NOBEL PRIZE-WINNING RESEARCH

RNA interference (RNAi) is a breakthrough in understanding how genes are regulated in cells. It also represents a completely new approach to drug discovery and development. The 2006 Nobel Prize for Physiology or Medicine, awarded to Craig Mello and Andrew Fire, recognised the importance of RNAi as a major scientific discovery.

join-our-team

JOIN OUR TEAM

As we pursue our goal of becoming a commercial organisation that can independently deliver medicines to patients, we are seeking individuals with diverse skills, experiences, and backgrounds to help us build a world-class team. We are based in Cambridge, USA, with offices in Zug, Switzerland, and Maidenhead, UK, but we are also hiring throughout Europe.

View current job openings ›

CONTACT US

Alnylam UK Ltd.

Braywick Gate, Braywick Road, Maidenhead, Berkshire SL6 1DA

info@alnylam.co.uk
+44 (0) 1255 444 400

For medical information, clinical trial questions or to report an adverse event or product complaint:

Toll: +44 1628878592
Toll-free: 08001412569 (also hidden caller ID)

medinfo@alnylam.com

Patient Organization Support

View lists of the past UK patient organizations that Alnylam supported in:

Joint Working Agreements

View the Executive Summaries for Joint Working Agreements with Alnylam UK below:

Live Joint Workings

Completed Joint Workings

UK Disclosure Reports

UK Disclosure Reports are available on the ABPI Disclosure UK website.
The UK Transparency Reporting Methodological Note can be viewed here.

Product Information

For information on Alnylam products, please see:

Reporting of Side Effects

Reporting of side effects: If you have any side effects, talk to your doctor, pharmacist, or nurse. This includes any possible side effects not listed in the package leaflet. You can also report side effects directly via the Yellow Card Scheme. By reporting side effects, you can help provide more information on the safety of this medicine.

Alnylam UK Ltd.

Date of prep: September 2024
Corp-UK-00045